生物標記相關的合作與許可協議（2016-2026 年）

生物標記相關交易的明確指標

生物標記合作是由數據、藥物發現和精準醫療策略驅動的，其合約結構反映了生物標記在標靶識別、患者分層和臨床開發中的作用。

本報告對超過 590 項與生物標記相關的合作關係和許可協議進行了全面系統的分析，清楚地展示了夥伴關係在整個市場中的設計、談判和執行情況。

清楚了解市場標準

本報告將使您對生物標記交易的實際結構有清晰的了解，從而使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解合約條款如何因應用程式、資料類型和合作夥伴概況而異。
• 支持基於證據的評估和合約結構確定。
• 內部討論應基於實際交易數據，而不是假設。
• 了解大型公司如何處理交易
• 在以數據主導和研究為重點的環境中，我們將合作夥伴行為和迭代交易結構視覺化。
• 全面了解交易結構和執行情況
• 本報告提供關鍵交易資料以及相關合約文件，使您能夠詳細了解實際合約的構成方式。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度至關重要，尤其是在藥物發現和開發的早期階段，對於了解生物標記夥伴關係中價值、風險和控制是如何分配的至關重要。
• 它旨在促進實際的業務發展和策略制定。

本報告主要用於以下用途：

• 建構和評估生物標記和藥物主導驅動的交易。
• 在清晰的市場環境下準備談判
• 評估數據、平台和合作機會。
• 支援穩健且引人注目的數據驅動型內部策略
• 本報告內容
• 超過590項與生物標記相關的合作和許可協議
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 可全文搜尋的合約目錄（依公司、應用程式和資料類型）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 交易趨勢分析、關鍵交易和活躍負責人
• 關於生物標記交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易報告和合約層面的深入分析，提供了關於如何建立、談判和評估生物標記合作關係的可靠、基於證據的參考資料。

目錄

執行摘要

第1章：引言

第2章：生物標記交易趨勢

• 介紹
• 生物標記相關交易的趨勢
• 生物標誌領域最活躍的交易者
• 與生物標記相關的交易（按交易類型）
• 與生物標記相關的交易（按治療領域分類）
• 生物標誌相關交易（按行業分類）
• 生物標記相關交易的條款與條件

第3章：與主要生物標記相關的交易

• 介紹
• 與主要生物標記相關的交易（以價值計）

第4章：生物標誌領域最活躍的相關人員

• 介紹
• 生物標誌領域最活躍的交易者
• 最活躍的生物標誌交易商的公司簡介

第5章：生物標誌合約交易目錄

• 介紹
• 生物標記合約交易目錄

第6章：依技術類型分類的生物標記交易

• 特價優惠列表
• 交易清單 - 生物標記交易（按公司分類）（AZ）
• 交易清單 - 與生物標記相關的交易（按交易類型分類）
• 交易清單 - 與生物標記相關的交易（按治療領域分類）
• 交易類型的定義
• 關於這家研究公司
• 當前夥伴關係
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for biomarker dealmaking

Biomarker partnering is driven by data, discovery, and precision medicine strategies, with deal structures reflecting the role of biomarkers in target identification, patient stratification, and clinical development.

This report provides a comprehensive and structured analysis of 590+ biomarker collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how biomarker deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by application, data type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a data-driven and research-intensive landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within biomarker partnerships, particularly in early-stage discovery and development contexts.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark biomarker and discovery-driven transactions
• Prepare for negotiations with well-defined market context
• Evaluate data, platform, and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 590+ biomarker collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, application, and data type)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for biomarker dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how biomarker partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

• 2.1. Introduction
• 2.2. Biomarker deals over the years
• 2.3. Most active biomarker dealmakers
• 2.4. Biomarker deals by deal type
• 2.5. Biomarker deals by therapy area
• 2.6. Biomarker deals by industry sector
• 2.7. Deal terms for biomarker deals
  • 2.7.1 Biomarker deals headline values
  • 2.7.2 Biomarker deal upfront payments
  • 2.7.3 Biomarker deal milestone payments
  • 2.7.4 Biomarker royalty rates

Chapter 3 - Leading biomarker deals

• 3.1. Introduction
• 3.2. Top biomarker deals by value

Chapter 4 - Most active biomarker dealmakers

• 4.1. Introduction
• 4.2. Most active biomarker dealmakers
• 4.3. Most active biomarker deals company profiles

Chapter 5 - Biomarker contracts dealmaking directory

• 5.1. Introduction
• 5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

• Deal directory
• Deal directory - Biomarker deals by company A-Z
• Deal directory - Biomarker deals by deal type
• Deal directory - Biomarker deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Biomarker deals since 2016
• Figure 2: Active biomarker dealmaking activity since 2016
• Figure 3: Biomarker deals by deal type since 2016
• Figure 4: Biomarker deals by therapy area since 2016
• Figure 5: Biomarker deals by industry sector since 2016
• Figure 6: Biomarker deals with a headline value
• Figure 7: Biomarker deals with an upfront value
• Figure 8: Biomarker deals with a milestone value
• Figure 9: Biomarker deals with a royalty rate value
• Figure 10: Top biomarker deals by value since 2016
• Figure 11: Most active biomarker dealmakers since 2016
• Figure 12: Biomarker deals by technology type since 2016